Unibest

Pharmaceutical intermediates

Nafamostat mesylate Intermediates

3 pharmaceutical intermediates for Nafamostat mesylate. Indication: Pancreatitis; Disseminated Intravascular Coagulation.

提交项目All intermediates

About Nafamostat mesylate

Indication
Pancreatitis; Disseminated Intravascular Coagulation
Approved Date
10/01/1986

Available intermediates

3 intermediates currently listed for Nafamostat mesylate. Request specifications, documentation or a quotation for any item below.

Nafamostat mesylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
6-Cyano-2-naphthol52927-22-7//
6-Amidino-2-naphtol methanesulfonate82957-06-0//
4-Guanidinobenzoic acid hydrochloride42823-46-1//

Other programs under N

Nebivolol HydrochlorideNemorexantNeratinib/ PyrotinibNilotinibNintedanib EsylateNiraparib

Building toward Nafamostat mesylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →